Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

VinFuture foundation announces 2022 VinFuture webinar series for nominators

Vingroup

HANOI, VIETNAM – Media OutReach – 24 March 2022 - As part of the sequence of activities for the second VinFuture Prize season, VinFuture Foundation has officially launched a series of six webinars in six different time zones around the world. This series of events aims to provide information directly to scientists across the globe and attract the most outstanding nominations to promote post-COVID-19 reconstruction and sustainable development. The webinar series will take place via Zoom from March 23 to April 19, 2022 and will be tailored for distinct geographic regions and time zones, including: US East and West Coasts, Europe, Africa, Asia, and Oceania. The webinars will be led by members of the VinFuture Prize Council and Pre-screening Committee and will feature the prize laureates from the first season. The second VinFuture Prize season, themed "Reshaping and Reviving", is focused on inventions and scientific initiatives accelerating the world's reconstruction and sustainable development following the COVID-19 pandemic. Since its official launch on February 16, 2022, the second season has received immense support from the global scientific community, with more than 1,000 organizations and individuals from 81 countries participating as nominators for the prize. To date, the scientific community in Asia has contributed the highest number of nominators with 34% of the total share, followed closely by the Americas with 33%, Europe with 22%, Australia with 6%, and Africa with 5%. The webinar series aims to provide the latest information directly to scientists worldwide and promote diversity and breadth in all potential areas. Through this series, VinFuture will address inquiries and concerns about the nomination process as well as share practical and inspirational perspectives from members of the Pre-screening Committee, the Prize Council, and especially the first season’s laureates. VinFuture Prize is an annual international award for breakthrough scientific and technological inventions that have created, or have the potential to create, meaningful changes in people's lives. Despite being a new award, with the mission of serving humanity and a selection process with high integrity and transparency, VinFuture has already built a strong reputation in the global scientific community. In the first season, VinFuture received nearly 1,200 nomination submissions from six continents around the world just four months after officially launching the nomination portal. VinFuture's nominators include institutes of higher education such as Harvard University, Cambridge University, Oxford University, and University of Tokyo, and prestigious organizations such as the National Institutes of Health of the United States, The Max Planck Society of Germany, Chinese Academy of Sciences, and more. The laureates of the first VinFuture Prize season are truly outstanding scientists that have been honored worldwide for their scientific achievements for humanity. The Grand Prize, with a value of US$3 million, was awarded to three prominent scientists: Dr. Katalin Karikó, Prof. Drew Weissman (USA) and Prof. Pieter Cullis (Canada) for the development of mRNA technology, paving the way for the production of effective vaccines to help prevent COVID-19 outbreaks, as well as potential vaccines for HIV, cancer, autoimmune and genetic diseases, helping to protect the future health of millions of people in the world. 2022 nomination portal: https://online.vinfutureprize.org/nomination For more details about the Prize: Detailed instructions about the nomination process and nomination form: https://online.vinfutureprize.org/nomination FAQs: https://vinfutureprize.org/faqs/ Information about the first VinFuture Prize: https://vinfutureprize.org/laureates/ * Webinar Series Agenda: About the VinFuture Foundation The VinFuture Foundation, established on December 20th, 2020, on the occasion of International Human Solidarity Day, is an independent, not-for-profit foundation established by billionaire Mr. Phạm Nhật Vượng, and his wife, Madam Phạm Thu Hương. The vision and mission of the Foundation is to create positive changes in the lives of millions of people in the world. The core activity of the Foundation is awarding the annual VinFuture Prizes to breakthrough scientific research and technological innovations that have already contributed or have the potential to contribute to the betterment of life for people. The VinFuture Prize consists of four prize categories, of which the Grand Prize – with a value of US$3 million – is one of the largest annual global prizes, and three additional Special Prizes, worth US$500,000 each, are dedicated to Female Innovator(s), Innovator(s) from Developing Country(ies), and Innovator(s) with Outstanding Achievements in Emerging Fields. In addition, the Foundation also conducts many activities to realize its mission, such as funding research, collaborating in academic development, and promoting STEM education. 2021 VinFuture Prize Laureates The Grand Prize: Dr. Katalin Karikó, Prof. Drew Weissman (USA) and Prof. Pieter Cullis (Canada) with their breakthrough research on mRNA technology for vaccines. Special Prize for “Innovators with Outstanding Achievements in Emerging Fields”: Professor Omar Yaghi (USA) with his work on discovering metal-organic frameworks (MOFs)' Special Prize for “Female Innovators”: Professor Zhenan Bao (USA) with her work on developing flexible electronics with the sensing properties of human skin. Special Prize for “Innovators from Developing Countries”: Prof. Salim S. Abdool Karim and Professor Quarraisha Abdool Karim (South Africa), for their Research on Pre-Exposure Prophylaxis with Antibiotics virus. Contact Details Vingroup v.nammh@vingroup.net Company Website https://vinfutureprize.org/

March 24, 2022 09:30 AM Eastern Daylight Time

Image

Lawsuit Challenging Nation’s Kidney Allocation Policy Is Dismissed

United Network for Organ Sharing

A lawsuit against United Network for Organ Sharing (UNOS) and the U.S. Department of Health and Human Services (HHS) challenging the nation’s current kidney allocation policy was dismissed on March 22 when plaintiffs withdrew their challenge, according to the District Court for the Southern District of Iowa. This follows a ruling in November of 2021 when the 8 th Circuit Court of Appeals ruled that the same plaintiffs were not likely to win on the merits of the case they presented. The kidney policy went into effect in March of last year. “The current kidney allocation policy is the result of respectful debate and discussion that included voices from across the donation and transplantation community,” said UNOS CEO Brian Shepard. “The numbers show that this policy is working as intended, and we thank our many dedicated OPTN volunteers, who donated their time to make our high-performing system even better.” Recent data shows kidney transplants for all populations have increased following the implementation of the policy, including a 22% increase in kidney transplants nationwide. UNOS will continue to monitor key metrics of the policy's performance to ensure that it continues as expected and to identify any areas for further development. “These numbers not only prove that the policy is increasing equity, but that the process that got us here was both effective and fair,” said UNOS Board President Matthew Cooper, M.D. “As we see the policy’s very real impact on the lives of kidney waitlist candidates and recipients, all of the patients, donor families, volunteers and others involved in developing this policy should be proud of what they have accomplished.” About UNOS United Network for Organ Sharing (UNOS) is a non-profit, charitable organization that serves as the Organ Procurement and Transplantation Network (OPTN) under contract with the federal government. The OPTN helps create and define organ allocation and distribution policies that make the best use of donated organs. This process involves continuously evaluating new advances and discoveries so policies can be adapted to best serve patients waiting for transplants. All transplant programs and organ procurement organizations throughout the country are OPTN members and are obligated to follow the policies the OPTN creates for allocating organs. Contact Details Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

March 23, 2022 06:20 PM Eastern Daylight Time

Going Back to Work: Who Will You Miss More? Your Family or Your Dog?

YourUpdateTV

With more people returning to the office, there’s a lot of anxiety and stress around what to do with four-legged family members who have become accustomed to having their pet parents at home. Recently, international dog trainer, Tom Davis, partnered with Wag! on a satellite media tour to talk about the type of care and training required to keep our pets happy. A video accompanying this announcement is available at: https://youtu.be/noALR-no8ig Over the past 2 years, many people adopted puppies and dogs during the pandemic. Right now, and over the next few weeks, millions of people will be returning to offices and workplaces for the first time. This transition period raises several issues for dogs: increased stress and anxiety, as well as lack of exercise and social play. In honor of National Puppy Day (March 23rd), Wag! conducted a national survey* and found that out of the 1,001 respondents, 62% percent have adopted a dog in the last two years during the pandemic. 41% of those dog parents returning to work said that they’ll miss their dogs even more than their kids or spouses. Out of those new dog parents, 76% are nervous about pet care challenges upon returning to work in- person. Some other key highlights include: Dogs are the best medicine: 93% say parenting a dog has provided them mental health support, while 48% say that dog parenting has decreased their anxiety. Puppy love is real: 37% say that the most surprising thing about parenting a new puppy was the overwhelming amount of love for their new friend Pet insurance is the single biggest challenge for new dog parents: 63% of respondents expressed surprise at how much time, effort and money was required for pet insurance, more than any other challenge of becoming a new pet parent. Dogs and parents can both suffer behavioral issues/anxiety being separated from each other. Services like Wag!, which connects Pet Parents with local Pet Caregivers for dog walking and longer drop-ins for play time, can give your dog the much-needed stimulation, and peace-of-mind for pet parents. Like human health insurance, it’s important to also get insurance for our pets. Pets are our family, and their health is just as important. WagWalking.com is a great resource for more information on pet insurance and wellness. For more information on the survey and Wag! check out WagWalking.com About Tom Davis: Tom Davis is an international dog trainer who specializes in dog training based on canine behavior, and he is known for taking in some of the hardest behavior modification training cases. His natural ability to understand and connect with dogs allows him to breakthrough problems, such as reactivity and disobedience. Tom knows that educating people about their dogs, and changing negative behaviors, is what he was put on this Earth to do. Tom spends the first several hours of his weekdays with his online dog training students, who are located across the United States and all over the world. Several times per month, Tom boards a plane to work with out-of-state clients, including professional athletes, musicians, actors and politicians. And most of his summers are spent studying with wolves in Colorado, allowing him to understand the canine with full complexity. Tom is also an official mentor trainer for the Animal Behavioral College, where his responsibilities include fine-tuning and mentoring graduating seniors. He plays a critical role in ensuring each student has the capability and canine skills to successfully graduate and enter into their professional career. About Wag!: Wag! is the #1 app for pet parents, offering options for 5-star dog walking, pet sitting, expert pet advice, and training from local pet caregivers nationwide. Wag!'s community of 400,000 pet caregivers are pet people, and it shows. Making pet parents happy is what Wag! does best. With safety and happiness at the forefront, pet caregivers with Wag! have a trusted record of experience with nearly 12 million pet care services across all 50 states, resulting in more than 96% of their reviews earning 5 stars. Survey Methodology Summary: * This sample of 1001 U.S. adults (18 years or older), all of whom are dog parents of at least one dog adopted, purchased or gifted to them within the past 2 years, was surveyed between February 14, 2022 and February 17, 2022. DKC Analytics conducted and analyzed this survey with a sample procured using the Pollfish survey delivery platform, which delivers online surveys globally through mobile apps and the mobile web along with the desktop web. No additional weighting has been applied to the sample. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

March 23, 2022 02:14 PM Eastern Daylight Time

Video

Psychedelic Pharmaceutical Startup Ninnion Announces Formation of World Renowned Scientific Advisory Board

Ninnion

Ninnion, a clinical-stage pharmaceutical company focused on developing next-generation psychedelic therapeutics today announced the formation of its Scientific Advisory Board (SAB). The board is composed of key opinion leaders in pharmaceutical development and psychedelics research, including Rick Strassman, MD, Charles B Nemeroff, MD, and chaired by Bill W. Massey, PhD, Ninnion’s Chief Development Officer. “The level of experience and expertise embodied in our Scientific Advisory Board is absolutely world-class. The SAB members bring a great balance of scientific, drug development and clinical expertise to Ninnion’s programs. Their guidance will be a tremendous asset in navigating the uncharted waters of psychedelic drug development,” said Bill W Massey, Chief Development Officer of Ninnion. The new SAB is composed of world renowned leaders in the areas of psychedelic research and drug development from top-tier organizations including Johns Hopkins, the Karolinska Institute and University of Texas, Austin. The SAB will work closely with Ninnion leadership, assisting with scientific judgments related to research and pipeline development. “I’m delighted to serve as a member of Ninnion’s Scientific Advisory Board - this is an opportunity to work together with the best minds in the psychedelic pharmaceutical industry during a time of significant growth and discovery. Collectively we will aim to guide Ninnion through the development of its current pipeline and are committed to following the science as we move forward in developing thoughtful, evidence-based solutions,” said Rick Strassman, MD. Ninnion’s research and development efforts currently focus on advancing second and third generation psychedelic therapies, which will ultimately empower patients with more accessible and affordable treatment opportunities. The SAB is an integral part of Ninnion’s vision to improve lives and forever change the landscape of today’s psychedelic pharmaceuticals. “I am honored to be surrounded by such great minds and key opinion leaders contributing to our Scientific Advisory Board. We are bringing the best minds together to create the next generation of psychedelic drug therapies to enhance the lives of patients, starting with those recovering from ischemic stroke.” said Jeremy Caudill, Founder and Chief Executive Officer of Ninnion. The founding members of the Ninnion Scientific Advisory Board are: Rick Strassman, MD, is a world renowned psychiatrist, psychopharmacologist, and pioneer in the advancement of clinical psychedelic research. After 20 years of intermission, Dr. Strassman was the first person in the United States to undertake human studies with psychedelic drugs, with his research on DMT and psilocybin in the early 1990s. Charles B. Nemeroff, MD, is an internationally recognized psychiatrist and researcher, specializing in the areas of Neuropsychopharmacology, Psychiatry, mood disorders, and trauma. He serves as the Matthew P. Nemeroff Professor and Chair of the Department of Psychiatry and Behavioral Sciences at the University of Texas at Austin Dell Medical School. Ede Frecska, MD, is a prolific author, researcher, and scholar with over 100 peer-reviewed papers and book chapters to his credit. He currently serves as Chief of Department at the National Institute of Psychiatry and Neurology in Budapest. Attila Szabo, Ph.D., is a distinguished scholar, researcher, and advocate in the areas of psychoneuroimmunology, immunopsychiatry, biological psychiatry, and the molecular biology of inflammation. His current research focuses on immune-brain interactions in severe mental disorders. Patrick Finan, Ph.D., is a trained clinical psychologist and expert in cognitive, behavioral, and affective non-pharmacological mechanisms and treatments for chronic pain. His research focuses on chronic pain and measurement and analysis of dynamic measures of pain and emotion captured in the course of daily life. Dr. Finan is currently the Principal Investigator or Co-Investigator on 8 NIH-funded grants totaling over $20 million. Brent Turnipseed, MD, is a dedicated mental health professional and entrepreneur whose work in behavioral health strives to elevate the standard of care for those living with severe mental illness. As a Medical Director and Co-founder of Roots Behavioral Health, Dr. Turnipseed focuses on providing affordable care and expanding access to emerging therapies like ketamine-assisted therapy (KAP) and psychedelic therapeutics. Mathias Egermark, MD, is a versatile and agile clinician and healthcare executive with a passion for building high-performing teams in clinical trials and development. Combining years of experience in clinical practice, pharmaceutical development, and business leadership, Dr. Egermark has distinguished himself as a leader in managing cross-functional teams in global settings. Jair Soares, MD, Ph.D., is a well-recognized researcher, academic, and clinician who has published over 300 peer-reviewed articles and book chapters in the field of psychiatry. He has been the recipient of numerous awards, academic and non-academic honors & appointments, including over two dozen awards for his work in the field of medicine and psychiatry. He is a board-certified psychiatrist and serves as Professor and Chairman of the Department of Psychiatry and Behavioral Sciences at UTHealth Houston Medical School, and director for the Center of Excellence on Mood Disorders. To find out more about Ninnion’s Scientific Advisory Board and or to view a full list of its members, visit www.ninnion.com/. About Ninnion Headquartered in Austin, Texas, Ninnion is a pharmaceutical company on a mission to build a fully integrated pharmaceutical psychedelics eco-system leveraging the latest AI drug discovery, development, cGMP manufacturing, commercialization, patient clinics and specialty pharmacy distribution network designed for the next frontier of psychedelic medicine. Focused on the payer-reimbursed market, Ninnion has begun developing a pipeline of next generation psychedelic therapies with a clinical focus on brain injury, chronic pain, inflammation, and addiction disorders. To learn more, visit www.ninnion.com. Contact Details Jive PR + Digital Ashley Areeda +1 734-891-4013 aareeda@jiveprdigital.com

March 23, 2022 12:18 PM Eastern Daylight Time

Modivcare Establishes Transportation Provider Advisory Council to Capture Voice of Community-Based Transportation Providers

Modivcare

Modivcare Inc. (“Modivcare”) (Nasdaq: MODV), a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions, announced today that it has established a national Transportation Provider Advisory Council (TPAC) to gather feedback and perspective from representatives of its network of 5,500 transportation providers. National in scope, the TPAC includes members from each major region of the U.S. While out-of-network transportation providers may be consulted on occasion, the TPAC will generally consist of contracted in-network providers of any size who enthusiastically share with Modivcare candid feedback, improvements, innovations, and forward-looking recommendations. In addition to helping Modivcare develop a deeper understanding of customer perspectives and experiences, the TPAC enables Modivcare to obtain transportation provider input in establishing new innovative services, while also improving existing services and processes. The TPAC will meet on a quarterly basis and be led by a designated Modivcare council chair and assistant chair. “Modivcare is deeply committed to developing strong, productive relationships within our nationwide network of community-based transportation providers, so that we can create a greater sense of partnership between us, and in turn, a consistent patient experience,” said Dan Greenleaf, President and CEO of Modivcare. “We are proud to announce the establishment of our Transportation Provider Advisory Council, which will provide valuable, actionable information that will improve our ability to support our customers.” “I am honored and take with great responsibility being asked to participate on this council,” said David Cason, President and CEO of New Mexico-based Shuttle Ruidoso, a TPAC member. “I was recently elected to lead a coalition of approximately 35 other transportation providers, and I hope to bring to the council not only the single voice of Shuttle Ruidoso but also a shared voice of all the providers in our state's network.” “As an NEMT provider, the most important factor in our business is having empathy for our customers. It is our foundation,” said Brisa Berumen-Dixon, CEO of Illinois-based Seabreeze Non-Emergency Medical Transportation, a TPAC member. “I am proud to join the council to share our employees’ and customers’ experiences with Modivcare as we work towards the shared goal of breaking down health-equity barriers.” Modivcare’s non-emergency medical transportation (NEMT) services provide patients access to safe and reliable rides to health services. Working with local, community-based transportation providers, Modivcare is the largest broker of NEMT in the nation and brings more than 35 years of experience to its transportation providers and more than 75 million trips managed annually for 30 million patients across the United States. # # # # About Modivcare Modivcare Inc. (“Modivcare”) (Nasdaq: MODV) is a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions for public and private payors and their patients. Our value-based solutions address the social determinants of health (SDoH), enable greater access to care, reduce costs, and improve outcomes. We are a leading provider of non-emergency medical transportation (NEMT), personal and home care, remote patient monitoring, medication management and meal delivery. Modivcare also holds a minority equity interest in CCHN Group Holdings, Inc. and its subsidiaries (“Matrix Medical Network”), which partners with leading health plans and providers nationally, delivering a broad array of assessment and care management services to individuals that improve health outcomes and health plan financial performance. To learn more about Modivcare, please visit www.modivcare.com. Contact Details Kate Zerone Director, Ombudsman & Communications kate.zerone@modivcare.com Amendola Communications Kim Warth kwarth@acmarketingpr.com

March 23, 2022 09:30 AM Eastern Daylight Time

SleepX applies to the Helsinki Committee for approval on its clinical trial with the SleepX PRO smartphone application

Appyea

SleepX, a subsidiary of AppYea (OTC: APYPD) focusing on the development of accurate wearable monitoring solutions to treat sleep apnea and snoring, announces it has applied to the Helsinki Committee for approval to begin its planned clinical trial on the SleepX PRO application. This follows the company’s recent update that it intends to test the SleepX Pro application at a hospital sleep lab. The trial is the first step towards applying for an FDA approval under the first-of-its-kind medical device category for contactless detection of sleep apnea to be performed through the Artificial Intelligence (AI) analysis of breathing during sleep. As the request is submitted under a medical device category and the trial is touchless, the company expects the process to be quick and take up to a few months. SleepX Pro which is designed to diagnose sleep apnea using only a smartphone, requiring no physical contact with the subject. The global sleep apnea devices market size is valued at USD 3.7 billion as of 2020 with a 6.2% CAGR, reaching USD 6.1 billion by 2028, according to Grand View Research’s report. “Poor sleep is associated with the compromised immune system, heart problems, reduce physical and mental performance, mood problems, obesity and many other health problems”, said Neil Kline, Founder & former CEO of the American Sleep Association, and a SleepX Board Member. “Unfortunately, most people with sleep disorder breathing problems, like sleep apnea, are undiagnosed and untreated. Our goal in this unique technology is to raise the awareness to the problem and to improve people’s awareness that they can live healthier and more fulfilling lives.” “SleepX PRO makes for a unique, quick and friendly diagnosis tool that will prevent subjects from having to spend nights at sleep labs while saving the healthcare system and insurance companies hundreds of millions of dollars”, said Boris (Bary) Molchadsky, President and CEO of SleepX, and Chairman at AppYea. “We plan to make our diagnosis solution highly accessible, so people get tested easily. SleepX is an Israeli research and development company recently acquired by AppYea. The company had developed a unique product for monitoring and treating sleep apnea and snoring. The technology is protected by several international patents and the company plans to start serial production in 2022. The company currently focuses its activities on the development and commercialization of its flagship product DreamIT. Legal Notice Regarding Forward-Looking Statements This release includes forward-looking statements. Such statements involve risks and uncertainties which could cause actual results to differ materially from those set forth herein. No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. Although APYP believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, unanticipated losses, financial condition and stock price, inability to carry out research, development and commercialization plans and other specific risks. APYP does not undertake any obligation to publicly update any forward-looking statement. Neither APYP nor SLEEPX are subject to the reporting requirements of the Securities and Exchange Commission under the Securities and Exchange Act of 1934 as amended. Contact Details Asaf Porat info@appyea.com Company Website http://www.appyea.com

March 23, 2022 07:53 AM Eastern Daylight Time

Centre for Neuro Skills California Facilities Awarded a Three-Year Accreditation by CARF International

Centre for Neuro Skills

Centre for Neuro Skills (CNS), a premier provider of treatment for traumatic and acquired brain injury, announced that its California facilities have been accredited for a period of three years by CARF International (formerly Commission on Accreditation of Rehabilitation Facilities). CARF International is an independent, nonprofit accrediting body whose mission is to promote the quality, value and optimal outcomes of services through a consultative accreditation process and continuous improvement that centers on enhancing the lives of persons served. The accreditation extends through Dec. 31, 2024. CARF-accredited organizations identify leadership that embraces the values of accountability and responsibility while demonstrating corporate social responsibility. “What sets CNS apart from other rehabilitation facilities is our focus on brain injury and/or stroke, and individualized treatment for each patient, with the end goal of maximizing independence and quality of life,” said David Harrington, president and chief operating officer of CNS. “The CARF accreditation process is very rigorous, and the report truly captures the heart and culture of CNS – the dedication, inspiration, integrity and innovation toward our patients, their families, our colleagues, and the field of rehabilitation. CNS is honored by the high praise in the surveyors’ accreditation report.” During the rigorous on-site peer review process, CNS demonstrated to a team of surveyors its dedication and commitment to offering programs and services that are measurable, accountable and of the highest quality. Areas of strength noted include: CNS has an extraordinary discharge process with a level of detail and coordination throughout, incorporating all disciplines, resources, and coordination of appointments and ongoing areas of need in all California locations. All locations in California quickly adapted to the COVID-19 pandemic by utilizing telehealth and developing protocols consistent with government guidelines, with capacity for rapid testing on-site for both staff members and patients. CNS’ facilities are well designed, spacious and nicely furnished. At the clinics, patients are happy with the opportunities for rehabilitation, while those in the residential treatment enjoy desirable neighborhoods with easy access to shipping, restaurants, banking and public transportation. All the apartments are in a gated, secure community, with access to a pool and fitness center. The Bakersfield location was praised for its compassion and support for its clinician teams, who have demonstrated incredible longevity, dedication and compassion for the jobs that they do. Patients, family members and referral sources report a very high level of satisfaction with the quality and intensity of services in both the residential and outpatient settings. Their comments include: “It’s a good feeling in my heart when I refer to them,” “I would choose CNS for myself,” “They have changed my life,” and “No one else could do all of this for our family.” Programs awarded accreditation to CNS’ California facilities include: San Francisco Bay Area (Emeryville) Interdisciplinary Outpatient Medical Rehabilitation: Brain Injury Specialty Program (Adults) Interdisciplinary Outpatient Medical Rehabilitation: Brain Injury Specialty Program (Children and Adolescents) Interdisciplinary Outpatient Medical Rehabilitation: Stroke Specialty Program (Adults) Residential Rehabilitation: Brain Injury Specialty Program (Adults) Residential Rehabilitation: Stroke Specialty Program (Adults) Bakersfield Interdisciplinary Outpatient Medical Rehabilitation: Brain Injury Specialty Program (Adults) Interdisciplinary Outpatient Medical Rehabilitation: Brain Injury Specialty Program (Children and Adolescents) Interdisciplinary Outpatient Medical Rehabilitation: Stroke Specialty Program (Adults) Los Angeles Area (Woodland Hills) Residential Rehabilitation: Brain Injury Specialty Program (Adults) Residential Rehabilitation: Stroke Specialty Program (Adults) Los Angeles Area (Tarzana) Interdisciplinary Outpatient Medical Rehabilitation: Brain Injury Specialty Program (Adults) Interdisciplinary Outpatient Medical Rehabilitation: Brain Injury Specialty Program (Children and Adolescents) Interdisciplinary Outpatient Medical Rehabilitation: Stroke Specialty Program (Adults) About Centre for Neuro Skills Centre for Neuro Skills is an experienced and respected world leader in providing intensive rehabilitation and medical programs for those recovering from all types of brain injury. CNS covers a full spectrum of advanced care from residential and assisted living to outpatient/day treatment. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas. For more information about Centre for Neuro Skills, visit: www.neuroskills.com, Facebook, Twitter, LinkedIn, YouTube. ### Media, please note: Visual assets, including photos, are available. To request an interview with CNS leadership, clinical staff or patients please contact Robin Carr at (415) 971-3991 or CNS@landispr.com. Contact Details Landis Communications Inc. Robin Carr +1 415-971-3991 cns@landispr.com Company Website https://www.neuroskills.com/

March 22, 2022 06:01 AM Pacific Daylight Time

SPARTA SCIENCE PARTNERS WITH INFLECT HEALTH TO REPLACE OUTDATED PHYSICIAN SCALES WITH AI-POWERED MOVEMENT HEALTH PLATFORM

Sparta Science

Sparta Science, an industry leader in movement health technology, has partnered with Inflect Health, the innovation hub of Vituity, to bring the Sparta Movement Health Platform to acute care clinics – and serve a chronic pain market forecast to reach $152 billion in this decade alone. Inflect will introduce Sparta Science’s innovative Movement Health Platform to seven of the innovation hubs’ clinics, replacing the outdated physician’s scale. Instead, a high-fidelity force plate collects individualized patient data through a simple, two-minute scan that generates over 3000 data points per second. The scans combine machine learning models and biomechanical analyses into a set of movement health metrics, movement qualities, and injury risk scores. “We are excited to begin this partnership with Inflect Health and we appreciate their investment in improving movement health for all individuals,” said Sparta Science CEO and founder Dr. Phil Wagner. “We are grateful to Inflect Health for recognizing the industry’s need to leverage advanced technologies using data science and AI to provide better personalized care.” Dr. Wagner, a physician and strength coach whose athletic career was cut short by a series of avoidable training injuries, originally led the development of the Movement Health Platform to help Navy SEALS and professional athletes. Sparta Science is now partnering with healthcare organizations to make this technology available to all patients. “As an industry, we’re only scratching the surface of what can be known about improving movement health,” said Andrew Smith, President of Inflect Health. “Through our partnership with Sparta Science and the help of the cutting-edge Sparta Movement Health Platform we look forward to serving key roles across the healthcare value spectrum, from diagnostic and preventative to rehabilitation and monitoring.” Formed by Vituity in December 2020, Inflect Health is a patient-centric healthcare innovation hub with access to 5,000 doctors and clinicians, 1,500 scribes, and over 300 hospitals, with frontline providers in some of the nation’s most acute care settings. Inflect Health capitalizes on its frontline care delivery experience, wide distribution channels, and access to small- to medium-sized enterprises across the entire healthcare space, to address local, community-based healthcare problems without the bureaucracy concerns that impede establishment healthcare organizations. ABOUT SPARTA SCIENCE: Sparta Science was founded with the vision that everybody should be able to move freely, without physical limitations, for as long as possible. Since bringing on our first customer in 2014, we’ve grown into a global full-stack movement health platform. Trusted by organizations spanning the healthcare, government, and sports industries, our platform empowers organizations to provide a better standard of care. Today, we’re ruthlessly focused on studying human movement and creating innovative ways to measure, monitor, and improve movement health. For more information, visit SpartaScience.com or follow us on Twitter and LinkedIn @SpartaScience. ABOUT INFLECT HEALTH: Inflect Health is a catalyst for better care. Headquartered in the San Francisco Bay Area with offices across America, Inflect Health provides guidance and financial support to early-stage healthcare and healthtech companies building promising solutions that offer to meet the needs of today’s evolving healthcare landscape. As the innovation hub of Vituity, a physician-owned multi-specialty partnership, Inflect Health has robust access to 5,000 doctors and clinicians, health systems, and other key industry players. This access allows Inflect Health to be a catalyst for consistent care improvement and innovative health technologies, by connecting innovators to capital, physicians, and patients in real-time. For more information on Inflect Health, including its portfolio, partners, services, and networking opportunities, visit www.InflectHealth.com or find Inflect Health on LinkedIn or Twitter @InflectHealth. ABOUT VITUITY: For 50 years, Vituity has been raising the standard of care and transforming how, when, and where care is delivered. As a physician-owned and -led multispecialty partnership, our 5,000 doctors and clinicians care for nearly 8 million patients annually across 450 practice locations and nine acute care specialties. Vituity’s patient focus and commitment to clinical excellence are the driving forces that place us at the heart of better care. Our front-line clinicians and business leaders develop healthcare solutions that improve outcomes for patients and hospitals. Our innovation hub, Inflect Health, identifies early-stage health-tech companies and facilitates a connection to physicians for testing, and our charitable foundation, Vituity Cares, extends our reach into communities that are most affected by healthcare disparities. Vituity is driven to continually transform healthcare through our collective passion for patients. Contact Details kglobal Jackie Hampton +1 443-814-0693 jacqueline.hampton@kglobal.com

March 22, 2022 09:00 AM Eastern Daylight Time

Roberts & Ryan Teams with Robert Irvine Supporting Our Nation's Veterans

Roberts & Ryan Investments, Inc.

Contact Details For Press Inquiries Please Contact Joe Pecoraro +1 917-658-8945 jpecoraro@roberts-ryan.com Company Website https://www.roberts-ryan.com

March 22, 2022 09:00 AM Eastern Daylight Time

Video

1 ... 190 191 192 193 194 ... 249